Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 8:12:768560.
doi: 10.3389/fimmu.2021.768560. eCollection 2021.

Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease

Affiliations
Review

Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease

Renáta Gáspár et al. Front Immunol. .

Abstract

Coronary artery disease (CAD) is one of the leading cause of mortality worldwide. Several risk factors including unhealthy lifestyle, genetic background, obesity, diabetes, hypercholesterolemia, hypertension, smoking, age, etc. contribute to the development of coronary atherosclerosis and subsequent coronary artery disease. Inflammation plays an important role in coronary artery disease development and progression. Pro-inflammatory signals promote the degradation of tryptophan via the kynurenine pathway resulting in the formation of several immunomodulatory metabolites. An unbalanced kynurenic pathway has been implicated in the pathomechanisms of various diseases including CAD. Significant improvements in detection methods in the last decades may allow simultaneous measurement of multiple metabolites of the kynurenine pathway and such a thorough analysis of the kynurenine pathway may be a valuable tool for risk stratification and determination of CAD prognosis. Nevertheless, imbalance in the activities of different branches of the kynurenine pathway may require careful interpretation. In this review, we aim to summarize clinical evidence supporting a possible use of kynurenine pathway metabolites as clinical biomarkers in various manifestations of CAD.

Keywords: IDO activity/detection; ischemic heart disease; kynurenic acid; liquid chromatography; mass spectrometry; personalized medicine; prediction; tryptophan.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic overview of the kynurenine pathway. Enzymes are indicated in italics. AA, anthranilic acid; ACMSD, aminocarboxymuconate-semialdehyde-decarboxylase; AMO, anthranilate 3-monooxygenase; 3-HAA, 3-hydroxyanthranilic acid; 3-HAO, 3-hydroxyanthranilate 3,4-dioxygenase; 3-HK, 3-hydroxykynurenine; IDO1 and or, IDO2, indoleamine 2,3-dioxygenase-1 and -2; KATs, kynurenine aminotransferase enzymes; KMO, kynurenine monooxygenase; KYN, kynurenine; KYNA, kynurenic acid; NAM, nicotinamide adenine mononucleotide; PA, picolinic acid; QA, quinolinic acid; QPRT, quinolinate phosphoribosyltransferase; TDO, tryptophan-2,3-dioxygenase; Trp, Tryptophan; XA, xanthurenic acid.

Similar articles

Cited by

References

    1. Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. . Global Epidemiology of Ischemic Heart Disease: Results From the Global Burden of Disease Study. Cureus (2020) 12(7):e9349–9. doi: 10.7759/cureus.9349 - DOI - PMC - PubMed
    1. Steenbergen C, Frangogiannis NG. Chapter 36 - Ischemic Heart Disease. In: Hill JA, Olson EN, editors. Muscle. Boston/Waltham: Academic Press; (2012). p. 495–521.
    1. Knuuti J. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes The Task Force for the Diagnosis and Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC). Russ J Cardiol (2020) 25(2):119–80. doi: 10.15829/1560-4071-2020-2-3757 - DOI
    1. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. . 2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation: The Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J (2021) 42(14):1289–367. doi: 10.1093/eurheartj/ehaa575 - DOI - PubMed
    1. Ali M, Girgis S, Hassan A, Rudick S, Becker RC. Inflammation and Coronary Artery Disease: From Pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Coron Artery Dis (2018) 29(5):429–37. doi: 10.1097/MCA.0000000000000625 - DOI - PubMed

Publication types